A holistic approach emphasizes lifestyle choices, nutrition, exercise, stress management, medications where appropriate, and ...

Short-selling is an interesting part of the stock market that can be dangerous and even controversial. Investors selling shares short are hoping that the price of certain stocks falls so that they can ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

The drug company is calling on insurers and federal programs to include coverage of obesity as a chronic disease.

Hims & Hers shares fell on Tuesday, a day after the company released fourth-quarter results that disappointed on gross margin and outlined changes to its weight loss business. The company reported ...

News About the Weight-Loss Drugs Is Pressuring HIMS Stock Eli Lilly disclosed today that it had started selling 7.5 milligram and 10 milligram vials of Zepbound, its popular weight-loss drug, for ...

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular weight-loss drugs today. Additionally, the FDA last week hindered the ...

Hims & Hers reported a double beat with Q4 revenue at $481M, a 95% YoY improvement, but faced an 18% stock drop after hours. Despite margin contraction due to new weight loss offerings, adjusted ...

Hims & Hers (HIMS) stock plunged 27% on Tuesday after the telehealth highflier indicated it may soon stop offering some compounded versions of weight-loss drugs. The company's fourth quarter ...

Stock in Hims & Hers Health was bound to tumble once it could no longer sell compounded versions of the weight-loss drug Wegovy at scale. But with lofty expectations about its remaining anti ...

Hims & Hers Health shares plunged 18% in extended trading on Monday after investors looked past better-than-expected revenue and earnings and focused instead on the disappointing gross margin. Get ...